

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A lyophilized composition of bone morphogenetic factor human MP52, which comprises bone morphogenetic factor human MP52 and mannitol wherein said bone morphogenetic factor human MP52 and mannitol are mixed at a weight ratio of 1: 5-50 and filtered prior to lyophilization.
2. (Canceled)
3. (Currently amended) The lyophilized composition according to claim 15, wherein said bone morphogenetic factor human MP52 is produced by means of a genetic engineering technology.
4. (Currently amended) A process for the preparation of a lyophilized composition of bone morphogenetic factor human MP52, which comprises adding mannitol to an aqueous solution of purified bone morphogenetic factor human MP52, filtering the resulting aqueous mixture solution and then lyophilizing the resulting aqueous mixture solution.
5. (Original) The process for the preparation of the lyophilized composition according to claim 4, wherein said bone morphogenetic factor human MP52 and mannitol are mixed at a weight ratio of 1 : 5-50.
6. (Original) The process for the preparation of the lyophilized composition according to claim 4, wherein said bone morphogenetic factor human MP52 is produced by means of a genetic engineering technology.

7. (Currently amended) A filtered solution of bone morphogenetic factor MP52, said solution comprising mannitol in a concentration of 0.5- 5 % (w/v).
8. (Previously presented) The solution of claim 7, further comprising a detergent in a concentration of 0.01 to 2.5 % (w/v).
9. (Previously presented) The solution of claim 8, wherein the detergent is a polyoxyethylenic detergent.
10. (Previously presented) The solution of claim 9, wherein the polyoxyethylenic detergent is Tween, Triton, Brij, or a polyoxyethylene-polyoxypropylene copolymer.
11. (Original) The solution of claim 9, wherein the detergent is Tween-80.
12. (Original) A method for the prevention of coloration of a lyophilized composition of MP52 wherein a solution according to claim 7 is subjected to lyophilisation yielding said lyophilized composition.
13. (Original) A method for the prevention of shrinking of a lyophilized composition of MP52, wherein a solution according to claim 7 is subjected to lyophilisation yielding said lyophilized composition.
14. (Original) A method for the prevention of aggregation at the redissolution of lyophilized composition of MP52, wherein a solution according to claim 7 is subjected to lyophilisation yielding said lyophilized composition.
15. (New) A lyophilized composition of bone morphogenetic factor human MP52, wherein said composition is made by mixing an aqueous solution of bone morphogenetic factor human MP52 and mannitol, filtering the resulting aqueous solution, filling a sterile vessel with the resulting filtered aqueous solution, and lyophilizing said filtered aqueous solution in said sterile vessel, wherein

said bone morphogenetic factor human MP52 and mannitol are mixed at a weight ratio of 1 : 5-50.